Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability

Psychopharmacology

Volumn 234, Issue 17, 2017, Pages 2643-2655

  Stiles, Mitchell F ^a   Campbell, Leanne R ^a   Graff, Donald W ^b   Jones, Bobbette A ^a   Fant, Reginald V ^c   Henningfield, Jack E ^c  

^a RAI Services Company   (United States)

^b CELERION   (United States)

^c PINNEY ASSOCIATES   (United States)

Author keywords

Abuse liability; Electronic cigarettes; Nicotine pharmacokinetics; Pharmacodynamics; Product liking; Subjective measures

Indexed keywords

CARBON MONOXIDE; COTININE; NICOTINE GUM; NICOTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMBUSTIBLE CIGARETTE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABUSE; DRUG EFFECT; DRUG SAFETY; DRUG UPTAKE; ELECTRONIC CIGARETTE; FEMALE; HEADACHE; HUMAN; INTENT TO USE PRODUCT AGAIN QUESTIONNAIRE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PRODUCT EFFECT QUESTIONNAIRE; PRODUCT LIKING QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMOKING; URGE FOR PRODUCT QUESTIONNAIRE; URGE TO SMOKE QUESTIONNAIRE; GINGIVA; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; TOBACCO;

ADULT; CROSS-OVER STUDIES; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; GINGIVA; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINE CHEWING GUM; RISK ASSESSMENT; TOBACCO PRODUCTS;

EID: 85021171316     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-017-4665-y     Document Type: Article

References (71)

1. Abrams DB (2014) Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA 311(2):135–136
2. Abrams DB, Niaura R (2015) The importance of science-informed policy and what the data really tell us about e-cigarettes. Isr J Health Policy Res 4(22). doi:10.1186/s13584-015-0021-z
3. Barbeau AM, Burda J, Siegel M (2013) Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract 8:5. doi:10.1186/1940-0640-8-5
4. Benowitz NL (2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 49:57–71. doi:10.1146/annurev.pharmtox.48.113006.094742
5. Benowitz NL, Hansson A, Jacob P III (2002) Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39:1107–1112
6. Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF (2006) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80:457–467
7. Calderon SN, Klein MA (2014) A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology 87:97–103
8. Caponnetto P, Campagna D, Papale G, Russo C, Polosa R (2012) The emerging phenomenon of electronic cigarettes. Expert Rev Respir Med 6:63–74. doi:10.1586/ers.11.92
9. Carter LP, Stitzer ML, Henningfield JE, O’Connor RJ, Cummings KM, Hatsukami DK (2009) Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomark Prev 18:3241–3262. doi:10.1158/1055-9965.EPI-09-0948
10. Cone EF, Fant RV, Henningfield JE (2012) Nicotine and tobacco. In: Mozayani A, Raymon L (eds) Handbook of drug interactions, 2nd edn. Humana Press, New York, pp 587–624
11. Etter JF, Bullen C (2013) A longitudinal study of electronic cigarette users. Addict Behav 39(2):491–494
12. Evans S, Hoffman A (2014) Electronic cigarettes: abuse liability, topography and subjective effects. Tob Control 23(Suppl 2):ii23–ii29
13. Fagerström KO (2012) Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res 14:75–78
14. Fagerström K, Eissenberg T (2012) Dependence on tobacco and nicotine products: a case for product-specific assessment. Nicotine Tob Res 14(11):1382–1390
15. Family Smoking Prevention and Tobacco Control Act (2009) Public Law 111–31
16. Fant RV, Pickworth WB, Henningfield JE (1997) The addictive effects of nicotine are related to the speed of delivery. In: Opitz K (ed) Nicotine as a therapeutic agent, immunity and the environment, vol 10. Gustav-Fisher, Stuttgart, pp 53–61
17. Fant RV, Henningfield JE, Nelson RA, Pickworth WB (1999) Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 8(4):387–392
18. Farsalinos KE, Polosa R (2014) Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 5(2):67–86. doi:10.1177/2042098614524430
19. Farsalinos K, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V (2013) Evaluation of electronic cigarette use (vaping) topography and estimation of liquid consumption: implications for research protocol standards definition and for public health authorities’ regulation. Int J Res Public Health 10:2500–2514. doi:10.3390/ijerph10062500
20. Farsalinos KE, Spyrou A, Stefopoulos C, Tsimopoulou K, Kourkoveli P, Tsiapras D, Kyrzopoulos S, Poulas K, Voudris V (2015) Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci Rep 5:11269. doi:10.1038/srep11269
21. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2010) Draft Guidance for industry: assessment of abuse potential of drugs. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf. Accessed 8 November 2016
22. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2015) Abuse deterrent opioids: evaluation and labeling. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf. Accessed 8 November 2016
23. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2017) Assessment of abuse potential of drugs. guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf. Accessed 18 January 2017
24. Food and Drug Administration, Center for Tobacco Products (CTP) (2012) Draft guidance for industry: modified risk tobacco product applications. https://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297751.pdf. Accessed May 8, 2017
25. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N (2014) Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 23(2):133–139. doi:10.1136/tobaccocontrol-2012-050859
26. Grudzinskas C, Balster RL, Gorodetzky CW, Griffiths RR, Henningfield JE, Johanson CE, Mansbach RS, McCormick CG, Schnoll SH, Strain EC, Wright C (2006) Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend 83(Suppl 1):S77–S82
27. Hajek P, Etter J, Benowitz N, Eissenberg T, McRobbie H (2014) Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction 109:1801–1810. doi:10.1111/add.12659
28. Hatsukami DK (2013) Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products. Tob Control 22(Supple 1):i36–i37. doi:10.1136/tobaccocontrol-2012-050785
29. Hecht S, Carmella S, Kotandeniya D, Pillsbury M, Chen M, Ransom B, Isaksson V, Thompson E, Murphy S, Hatsukami D (2015) Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res 17:704–709. doi:10.1093/ntr/ntu218
30. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61(5):743–750
31. Henningfield JE, Hatsukami DK, Zeller M, Peters E (2011) Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend 116:1–7
32. Houstsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML (2002) Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 72:559–568
33. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984) Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 98:334–341
34. Johnson MW, Bickel WK (2003) The behavioral economics of cigarette smoking: the concurrent presence of a substitute and an independent reinforcer. Behav Pharmacol 14(2):137–144
35. Johnson MW, Bickel WK, Kirshenbaum AP (2004) Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. Drug Alcohol Depend 74(3):253–264
36. Jones HE (2004) Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2(2):4–20
37. Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV (2001) Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control 10(3):201–203. doi:10.1136/tc.10.3.201
38. McColl S, Sellers EM (2006) Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 83S:S52–S62
39. McNeill A, Brose LS, Calder R, Hitchman SC, Hajek P, McRobbie H (2015) E-cigarettes: an evidence update. A report commissioned by Public Health England. https://www.gov.uk /government/uploads/system/uploads/attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf. Accessed 13 January 2017
40. Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE, Nides MA, Kiley JP (1996) Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest 109:438–445
41. Murray RP, Connett JE, Zapawa LM (2009) Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 11:1076–1082. doi:10.1093/ntr/ntp104
42. National Institute on Drug Abuse (2012) Medication assisted treatment for opioid addiction. https://www.drugabuse.gov/sites/default/files/tib_mat_opioid.pdf. Accessed 14 October 2016
43. Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012) Nicotine treatment of mild cognitive impairment. Neurology 78:91–101. doi:10.1212/WNL.0b013e31823efcbb
44. Niaura R (2016). Re-thinking nicotine and its effects. The Truth Initiative. http://truthinitiative.org/sites/default/files/ReThinking-Nicotine.pdf. Accessed February 3, 2017
45. Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerström K, Letlape K, Milton A, Polosa R, Ramsey J, Sweanor D (2014) Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 20:218–225. doi:10.1159/000360220
46. O’Connor RJ (2012) Non-cigarette tobacco products: what have we learnt and where are we headed? Tob Control 21(2):181–190. doi:10.1136/tobaccocontrol-2011-050281
47. Rass O, Pacek LR, Johnson POS, Johnson MW (2015) Characterizing use patterns and percentions of relative harm in dual users of electronic and tobacco cigarettes. Exp Clin Psychopharmacol 23(6):494–503
48. Reissig CJ, Harrison JA, Carter LP, Griffiths RR (2015) Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology 232(5):871–883
49. Royal College of Physicians of London (2000) Nicotine addiction in Britain. Lavenham Press, Ltd., Sudbury, pp 92–100
50. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997) Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130(4):352–361
51. Schuster CR, Henningfield J (2003) Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 70(Suppl 3):S1–S4
52. Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME (2000) Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 95(8):1185–1195
53. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T (2009) Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav 91:380–384. doi:10.1016/j.pbb.2008.08.012
54. Shihadeh A, Eissenberg T (2015) Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux. Nicotine Tob Res 17(2):158–162
55. Spindle T, Breland A, Karaoghlanian N, Shihadeh A, Eissenberg T (2015) Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement on plasma nicotine and subjective effects. Nicotine Tob Res 17:142–149. doi:10.1093/ntr/ntu186
56. Stitzer ML, de Wit H (1998) Abuse liability of nicotine. In: Benowitz NL (ed) Nicotine safety and toxicity. Oxford University Press, New York, pp 119–131
57. Substance Abuse and Mental Health Services Administration (2016) Buprenorphine. http://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine. Accessed 14 October 2016
58. The Expert Panel, Henningfield JE, Johanson CE, Sellers EM (2003) Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend 70(Suppl):S107–S114. doi:10.1016/S0376-8716(03)00103-0
59. Truth Initiative (2015) The truth about: electronic nicotine delivery systems. http://truthinitiative.org/sites/default/files/The_Truth_About_Electronic_Nicotine_Delivery_Systems.pdf. Accessed 13 January 2017
60. U. S. Department of Health and Human Services (2010) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. U. S. Government Printing Office, Washington, D. C
61. U. S. Department of Health and Human Services (2012) Draft guidance for industry: modified risk tobacco product applications. http://www.fda.gov/downloads/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/UCM297751.pdf. Accessed 13 January 2017
62. U. S. Department of Health and Human Services (2014) The health consequences of smoking - 50 years of progress: a report of the Surgeon General. Department of Health and Human Services, Public Health Service, Office of the Surgeon General. U. S. Government Printing Office, Washington, D. C
63. Vansickel AR, Eissenberg T (2012a) Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 15:267–270. doi:10.1093/ntr/ntr316
64. Vansickel AR, Cobb CO, Weaver MF, Eissenberg T (2010) A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomark Prev 19:1945–1953. doi:10.1158/1055-9965.EPI-10-0288
65. Vansickel AR, Weaver MF, Eissenberg T (2012b) Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction 107:1493–1500. doi:10.1111/j.1360-0043.2012.03791.x
66. Waldum HL, Nilsen OG, Nilsen T, Rørvik H, Syversen V, Sanvik AK, Haugen OA, Torp SH, Brenna E (1996) Long-term effects of inhaled nicotine. Life Sci 58:1339–1346
67. Warner KE, Slade J, Sweanor DT (1997) The emerging market for long-term nicotine maintenance. JAMA 278(13):1087–1092
68. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray, and inhaler. Psychopharmacology 149:198–202
69. Yan X, D’Ruiz C (2015) Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul Toxicol Pharmacol 71:24–34. doi:10.1016/j.yrtph.2014.11.004
70. Zeller M (2013) Reflections on the ‘endgame’ for tobacco control. Tob Control 22:i40–i41. doi:10.1136/tobaccocontrol-2012-050789
71. Zeller MR, Hatsukami D (2009) Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 18:324–332. doi:10.1136/tc.2008.027318